Phase 4 N=16 Treatment

Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia

Tachycardia, Ventricular

Bottom Line

View on ClinicalTrials.gov: NCT01901575 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Dec 2014

Primary outcome: Primary: Inhibition of Idiopathic Ventricular Tachycardia

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Remifentanil (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: NYU Langone Health
Primary completion: Apr 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Inhibition of Idiopathic Ventricular Tachycardia	—	—
PRIMARY PVC Suppression With Remifentanil Sedation	2	0.05

Summary

Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin

Eligibility Criteria

Inclusion Criteria

Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin
Patients between 18 and 65
ASA 1-3

Exclusion Criteria

ASA 4 and 5
Age 18 and 65

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01901575). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.